Patterson Leone D
SEC-identified person · CIK 1233539 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Nkarta, Inc. NKTX | Director | filed 2020 - 2026 |
| Kalaris Therapeutics, Inc. KLRS | Director | filed 2025 - 2026 |
| Zymeworks Inc. ZYME | EVP, Chief Bus & Fin Officer | filed 2024 - 2026 |
| Tenaya Therapeutics, Inc. TNYA | Chief Fin. and Bus. Officer | filed 2021 - 2024 |
| Eliem Therapeutics, Inc. ELYM | Director | filed 2021 - 2022 |
| Avalanche Biotechnologies, Inc. [AAVL] | Director · SVP, CFO, Interim Pres and CEO | filed 2016 - 2021 |
| Diadexus, Inc. vxgn | Chief Financial Officer | filed 2015 - 2015 |
| Transcept Pharmaceuticals Inc TSPT | Vice President, CFO | filed 2012 - 2014 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.